TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Tarsus Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$69.50+1.43 (+2.10%)

Close on Oct 19, 2026

Market cap: $3.02B
P/E (TTM): –
Dividend yield: 0.00%

Tarsus Pharmaceuticals, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	451	183	17	26	57	0	–	–
Research & Development	64	53	50	43	42	19	3.16	–
Selling, General & Admin	427	237	109	45	–	–	–	–
General & Administrative	–	–	–	45	25	8.17	1.14	–
Advertising Expenses	121	30	9.40	0	–	–	–	–
Operating Expenses	–	–	161	89	69	27	4.30	–
Total Costs & Expenses	522	304	161	89	–	–	–	–
Operating Income	-71	-121	-143	-63	-12	-27	-4.30	–
Interest Expense	8.94	7.85	3.35	2.20	0	–	–	–
Interest & Investment Income	16	15	10	3.50	–	–	–	–
Other Non-Operating Income	6.61	5.02	7.27	0.62	-1.62	0.19	-0.37	–
Gain (Loss) on Investments	0	-0.59	0.26	-0.27	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	0	-0.07	0	–	–
Pretax Income	-64	-116	-136	-62	-14	-27	–	–
Income Tax Expense	2.06	0	0	0.00	0.06	0.00	0.00	–
Net Income	-66	-116	-136	-62	-14	-27	-4.67	-1.32
EPS (Basic)(per share)	-1.59	-3.07	-4.62	-2.52	-0.67	-4.32	-1.98	–
EPS (Diluted)(per share)	-1.59	-3.07	-4.62	-2.52	-0.67	-4.32	-1.98	–
Shares Outstanding (Basic, Weighted)(shares)	42	38	29	25	21	6.21	2.36	–
Shares Outstanding (Diluted, Weighted)(shares)	42	38	29	25	21	6.21	2.36	–
Dividend per Share(per share)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -8.0%
Net margin: -7.7%
Return on equity, FY2025: -23.4%

Financial strength

Current ratio: 3.20
Debt to equity: 0.21
Debt to assets: 11.9%
Cash to current liabilities: 116.4%

Valuation

P/E ratio: –
Price to sales: 4.97
Price to book: 8.70
Dividend yield: 0.00%